

1 July 2016

Announcements  
National Stock Exchange of Australia  
PO Box 283  
NEWCASTLE NSW 2300

**Market Announcement – Indicative Timetable for Proposed Share Split**

Further to the announcement of **iQN Ltd's** (the Company) Extraordinary General Meeting scheduled for Tuesday, 5 July 2016, to consider the Company's proposal to divide the current Ordinary Share allocation in the order of 3 shares per existing share, the Company provides the following indicative timetable for completion of the proposed share split.

**Indicative Timetable**

	<b>Event</b>	<b>Indicative date</b>
1.	Date of EGM	Tuesday, 5 July 2016
2.	Notification to NSX that Share split is approved	Tuesday, 5 July 2016
3.	Last day for trading in the pre-split securities Orders purged C.O.B	Wednesday, 6 July 2016
4.	Commencement of Security Trading Halt in order to allow finalisation of trades - <b>Effective Date</b>	Thursday, 7 July 2016
5.	Last day for registration of transfers with share registry- <b>Record Date</b>	Friday 8, July 2016
6.	First day that notice and registration of securities post-share split can be sent	Monday, 11 July 2016
7.	Notices and holding statements sent to all security holders - <b>Issue date</b>	Tuesday, 12 July 2016
8.	Resumption of normal trading	Wednesday 13, July 2016
9.	First settlement date (T+2)	Friday, 15 July 2016

For and on behalf of the Board.



**Kelvin Boateng**  
Company Secretary  
iQnovate Ltd

Sydney: Level 7, 222 Clarence Street, Sydney, NSW 2000, Australia • Phone: +61 2 8239 5400  
New York: 400 Madison Avenue, Suite 10A, New York City NY10017 USA | +1 212 433 2630  
London: 20 Broadwick Street, London, W1F-8HT, UK • Phone: +44(0)2077121508

*Safe Harbor Statement*

*Any statements in this announcement that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with IQnovate's business can be found in its periodic filings with the National Stock Exchange of Australia.*

**SOURCE IQnovate Ltd**

*IQnovate Ltd is a life science organisation, providing intellectual property asset management services and scientific advice to the global Biopharmaceutical industry.*

*Whether the asset is a pharmaceutical, medical device, technology platform or a compound in development, iQnovate will effectively manage your asset through its complete life cycle, from clinical trials right through to maturity.*

*iQnovate clients are pharmaceutical, biotechnology, medical device companies as well as financial institutions, academic and government organisations.*